Scilex 与 Biconomy 合作，探索其 $1B+ 数字资产的加密货币和金库策略。 Scilex partners with Biconomy to explore crypto and treasury strategies for its $1B+ digital assets.

2025年9月24日宣布,一家设在加利福尼亚的制药公司Scilex Holding Company于2025年9月24日与Biconomy.com签署一份不具约束力的谅解备忘录,探讨隐秘货币和财务管理战略。 Scilex Holding Company, a California-based pharmaceutical firm focused on non-opioid pain and chronic disease treatments, announced on September 24, 2025, a non-binding Memorandum of Understanding with Biconomy.com to explore cryptocurrency and treasury management strategies. 合作的目的是利用比科诺米的平台进行Scilex的数字资产全球贸易,其中可能包括Bitcoin和Etheum,其资产价值超过10亿美元。 The collaboration aims to use Biconomy’s platform for global trading of Scilex’s digital assets, potentially including Bitcoin and Ethereum, with assets valued at over a billion dollars. 该伙伴关系还将制定一项安全、符合要求和注重产出的财务战略,并利用比科诺技术获取金融数据,使数字资产货币化。 The partnership will also develop a secure, compliant, and yield-oriented treasury strategy and leverage Biconomy’s technology to access financial data for monetizing digital assets. Scilex市场销售用于神经病痛的ZTlido、用于偏头痛的ELYXYB和用于预防痛风的Gloperba,临床开发中有若干产品候选产品,包括用于静脉瘤的SP-102和用于急性疼痛的SP-103,其中一些产品被美国食品和药物管理局快速识别。 Scilex markets ZTlido for neuropathic pain, ELYXYB for migraines, and Gloperba for gout prevention, with several product candidates in clinical development, including SP-102 for sciatica and SP-103 for acute pain, some with FDA Fast Track designation. 谅解备忘录不保证任何具体成果。 The MOU does not guarantee any specific outcomes.